Photo by Diana Polekhina on Unsplash
Recent studies have uncovered that the shingles vaccine, traditionally administered to prevent herpes zoster, may offer additional health benefits by reducing the risks of dementia and cardiovascular diseases.
Dementia Risk Reduction
A comprehensive study conducted in Wales analyzed health records of over 280,000 adults aged 71 to 88. The findings revealed that individuals who received the live-attenuated shingles vaccine, Zostavax, experienced a 20% lower risk of developing dementia over a seven-year period compared to those unvaccinated. This significant reduction was particularly notable among women. The study leveraged a unique public health policy from 2013, which offered the vaccine to individuals turning 79 that year, creating a natural experiment to assess the vaccine’s impact.
The protective effect against dementia is hypothesized to stem from the vaccine’s ability to prevent reactivation of the varicella-zoster virus, thereby reducing neuroinflammation—a known contributor to cognitive decline. Additionally, the vaccine may stimulate broader immune responses that help protect the brain.
Cardiovascular Benefits
In a separate large-scale study from South Korea, researchers examined medical data from over 1.2 million adults aged 50 and above. The study found that those who received the shingles vaccine had a 23% lower risk of experiencing cardiovascular events, including stroke, heart failure, and coronary heart disease. The most substantial protective effects were observed within the first two to three years post-vaccination, with benefits lasting up to eight years.
The underlying mechanism is believed to involve the vaccine’s role in preventing shingles-related inflammation in blood vessels, which can lead to cardiovascular complications. By averting the shingles infection, the vaccine likely reduces this inflammatory response, thereby lowering the risk of heart disease. Medical News Today
Implications for Public Health
These findings suggest that the shingles vaccine may serve as a valuable tool not only in preventing shingles but also in reducing the risks of dementia and cardiovascular diseases among older adults. Given the vaccine’s safety profile and the severity of these conditions, healthcare providers might consider discussing the broader benefits of shingles vaccination with eligible patients.
Further research, including randomized controlled trials, is necessary to confirm these associations and to understand the mechanisms involved. Nevertheless, the current evidence points to the shingles vaccine as a promising intervention for enhancing health outcomes in the aging population.
